Benzinga | Nov 5, 2020 04:33PM EST

Fate Therapeutics Q3 EPS $(0.68) Misses $(0.36) Estimate, Sales $7.56M Beat $6.97M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.36) by 88.89 percent. This is a 70 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $7.56 million which beat the analyst consensus estimate of $6.97 million by 8.44 percent. This is a 211.16 percent increase over sales of $2.43 million the same period last year.